High-dose Rybelsus trial shows greater HbA1c and weight reduction in Type 2 diabetes

According to DiaTribe Learn, Novo Nordisk has released initial results for a clinical trial testing Rybelsus at high doses, showing significant reductions in both HbA1c levels and weight in patients with type 2 diabetes, marking the greatest amount of weight loss ever seen to date from an oral glucose lowering agent.

Rybelsus is a semaglutide taken once-daily by mouth, rather than by injection and is prescribed for people with Type 2 diabetes, along with diet and exercise to help control blood sugar.

Results from the phase 3 trial showed that Rybelsus at experimental doses of 25mg and 50mg for 68 weeks outperformed a 14mg dose, which has been the maximum approved dose of Rybelsus thus far. Based on these results, which reveal an average HbA1c reduction of roughly 2 percentage points and an average weight reduction of 10% with the highest Rybelsus dose, Novo Nordisk plans to file for regulatory approvals of the 25mg and 50mg doses in the US and the EU later this year.

To read more CLICK HERE

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).

Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags